Topics

Clinical Trials About "AA21004 AA21004 Placebo Depressive Disorder Major" RSS

17:44 EST 17th January 2020 | BioPortfolio

We list hundreds of Clinical Trials about "AA21004 AA21004 Placebo Depressive Disorder Major" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "AA21004 AA21004 Placebo Depressive Disorder Major" on BioPortfolio

We have published hundreds of AA21004 AA21004 Placebo Depressive Disorder Major news stories on BioPortfolio along with dozens of AA21004 AA21004 Placebo Depressive Disorder Major Clinical Trials and PubMed Articles about AA21004 AA21004 Placebo Depressive Disorder Major for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of AA21004 AA21004 Placebo Depressive Disorder Major Companies in our database. You can also find out about relevant AA21004 AA21004 Placebo Depressive Disorder Major Drugs and Medications on this site too.

Showing "AA21004 AA21004 Placebo Depressive Disorder Major" Clinical Trials 1–25 of 34,000+

Extremely Relevant

Efficacy and Safety of Lu AA21004 in Acute Treatment of Major Depressive Disorder

The purpose of the study is to evaluate the efficacy and the tolerability of three fixed doses of Lu AA21004 in order to establish the appropriate clinical effective dose range in the treatment of Major Depressive Disorder.


Efficacy and Safety of Lu AA21004 in Adults With Major Depressive Disorder

The purpose of this study is to determine the effectiveness and safety of Lu AA21004, once daily (QD), in patients with Major Depressive Disorder.

Efficacy and Safety of Lu AA21004 in Acute Treatment of Major Depressive Disorder

The purpose of the study is to evaluate the efficacy and the tolerability of two fixed doses of Lu AA21004 in the acute treatment of Major Depressive Disorder.


Efficacy and Safety of Lu AA21004 in Acute Treatment of Major Depressive Disorder

The purpose of the study is to evaluate the efficacy and the safety of two fixed doses of Lu AA21004 in the treatment of Major Depressive Disorder.

Efficacy and Safety of Lu AA21004 in the Treatment of Subjects With Major Depressive Disorder

The purpose of this study is to determine the efficacy and safety of Lu AA21004, once daily (QD), in adults with major depressive disorder.

Efficacy and Safety Study of Lu AA21004 in Adults With Major Depressive Disorder

The purpose of this study is to evaluate the efficacy of Lu AA21004, once daily (QD), compared with placebo in adults with major depressive disorder.

Safety and Efficacy of Lu AA21004 in Adults With Major Depressive Disorder

The purpose of this study is to evaluate the efficacy, safety and tolerability of Lu AA21004, once daily (QD), compared with placebo in adults with major depressive disorder.

Efficacy and Safety of Lu AA21004 in Treating Adult Subjects With Major Depressive Disorder

The purpose of this study is to determine the efficacy and safety of once daily (QD) Lu AA21004 in adults with major depressive disorder.

Long-Term Study of Lu AA21004 in Patients With Major Depressive Disorder

The purpose of the study is to evaluate long-term safety and tolerability of Lu AA21004 over a period of 52 weeks in patients with Major Depressive Disorder having completed 6-week acute treatment.

Efficacy of Lu AA21004 in the Prevention of Relapse of Major Depressive Episodes

This study will evaluate the efficacy of Lu AA21004 in the prevention of relapse of major depressive episodes in patients who responded to open-label treatment with Lu AA21004.

Long-term Safety Study of Lu AA21004 in Patients With Major Depressive Disorder

The purpose of the study is to evaluate long-term safety and tolerability of Lu AA21004 over a period of 52 weeks in patients with Major Depressive Disorder (MDD) having completed 8-week acute treatment.

Efficacy and Safety of Lu AA21004 in Acute Treatment of Major Depressive Disorder in Elderly Patients

To assess the efficacy of Lu AA21004 (5mg daily) versus placebo in the acute treatment of depression by means of the change from baseline in the 24-item Hamilton Depression Scale total score after 8 weeks of double-blind treatment in elderly patients.

Relapse-prevention Study With Lu AA21004 in Patients With Generalized Anxiety Disorder

The study will evaluate the long-term maintenance of efficacy of Lu AA21004 in patients with Generalized Anxiety Disorder (GAD) who responded to acute treatment with Lu AA21004.

Efficacy and Safety of Lu AA21004 in Treating Generalized Anxiety Disorder

The purpose of this study is to evaluate the safety and efficacy of 2.5 mg and 10 mg of Lu AA21004, once daily (QD), in adults with generalized anxiety disorder

Study of Vortioxetine (Lu AA21004) in Major Depressive Disorder in Asian Countries

This study will be conducted with the aim of investigating the efficacy, safety and tolerability of 10 mg/day Vortioxetine in Asian patients compared to an approved active comparator (venlafaxine extended release 150 mg/day).

A Bioequivalence Study of the Lu AA21004 20 mg and 2×10 mg Tablets

The purpose of this study is to evaluate the bioequivalence of a single oral administration of a Lu AA21004 20 mg tablet in comparison with two of Lu AA21004 10 mg tablets in Japanese healthy adult participants.

Efficacy and Safety of Lu AA21004 for Treatment of Generalized Anxiety Disorder in Adults.

The purpose of this study is to evaluate the efficacy and safety of Lu AA21004, once daily (QD), in adults with Generalized Anxiety Disorders.

A Study of Brexpiprazole in Patients With Major Depressive Disorder

The purpose of this 14 week, randomized, double-blind, placebo controlled study is to assess the safety and efficacy of brexipiprazole to placebo as adjunctive treatment to an assigned open-label marketed antidepressant therapy (ADT) in patients with Major Depressive Disorder.

A Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Patients With Major Depressive Disorder

MIN-117C03 is a 6-week, 3-arm, randomized, double-blind, placebo-controlled study to investigate the safety and efficacy of MIN-117 in male and female patients with Major Depressive Disorder, aged 18 to 65 years. Approximately 324 patients will be randomly assigned to 1 of 3 treatment arms, including placebo, 5.0 mg MIN-117, or 2.5 mg MIN-117 in a 2:1:1 ratio.

Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)

Evaluating the efficacy of vortioxetine 10 mg/day and 20 mg/day versus placebo on depressive symptoms in adolescents (age ≥12 and ≤17 years) with a DSM-5™ (Diagnostic and Statistical Manual of Mental Disorders, 5th edition) diagnosis of Major depressive disorder (MDD).

A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Major Depressive Disorder

The study will evaluate the efficacy, safety, and tolerability of 450 milligrams (mg) of Rapastinel, compared to placebo in adult patients with major depressive disorder (MDD) who are at imminent risk of suicide.

Randomized, Placebo-Controlled Trial of an AMPAkine in Major Depressive Disorder

The purpose of this study is to test a candidate drug, Org 24448,in a phase II clinical trial in adult patients with moderately treatment-resistant unipolar major depressive disorder.

An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder

A Placebo Controlled Study Evaluating Efficacy, Safety and Tolerability of Medication in Patients with Major Depressive Disorder (MDD)

An 8 Week Study Of Adults Diagnosed With Major Depressive Disorder

A Placebo Controlled Study Evaluating Efficacy, Safety and Tolerability of Medication in Patients with Major Depressive Disorder (MDD)

Dose-Finding Study With Lu AA24530 in Major Depressive Disorder

The primary purpose of this study is to assess the efficacy in treating patients with Major Depressive Disorder of one or more doses of Lu AA24530 relative to placebo


More From BioPortfolio on "AA21004 AA21004 Placebo Depressive Disorder Major"

Quick Search